Literature DB >> 2683243

Heparin-induced thrombocytopenia.

P S Becker1, V T Miller.   

Abstract

There are two types of heparin-induced thrombocytopenia. Type I is more common, has an early onset, and is mild, transient, and benign. Type I is due to direct heparin-induced platelet aggregation and is rarely associated with thromboembolic sequela. Type II is infrequent, has a late onset, and is more severe. Type II is due to an immune-mediated platelet aggregation caused by IgG and IgM that becomes bound to platelets. In Type II, the antibody titers decline over several months; however, early reexposure can result in a catastrophic secondary immune response. Frequently, Type II is associated with life- or limb-threatening thromboembolic complications (white clots), including stroke.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2683243     DOI: 10.1161/01.str.20.11.1449

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  5 in total

1.  Why is the platelet count low: should I be concerned about heparin-induced thrombocytopenia?

Authors:  Christopher Lancaster; Joseph D Tobias
Journal:  J Pediatr Pharmacol Ther       Date:  2012-01

Review 2.  Glycoprotein IIb/IIIa inhibitor-induced thrombocytopenia: diagnosis and treatment.

Authors:  S M Said; J Hahn; E Schleyer; M Müller; G M Fiedler; M Buerke; R Prondzinsky
Journal:  Clin Res Cardiol       Date:  2006-12-08       Impact factor: 5.460

3.  [Implementing ambulatory prevention of thrombosis with low molecular weight heparin in plaster immobilization of the lower extremity].

Authors:  H J Kock; K P Schmit-Neuerburg; J Hanke; A Terwort; G Rudofsky; H Hirche
Journal:  Unfallchirurgie       Date:  1994-12

Review 4.  Severe thrombocytopenia and alveolar hemorrhage represent two types of bleeding tendency during tirofiban treatment: case report and literature review.

Authors:  Omer Celal Elcioglu; Abdullah Ozkok; Timur Selcuk Akpınar; Fatih Tufan; Murat Sezer; Sabahattin Umman; Sevgi Kalayoglu Besısık
Journal:  Int J Hematol       Date:  2012-07-06       Impact factor: 2.490

5.  [Thrombocytopenia in a patient with coronary artery disease after percutaneous coronary intervention].

Authors:  S M Said; R Prondzinsky
Journal:  Internist (Berl)       Date:  2008-05       Impact factor: 0.743

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.